Sugi Predict

Sugi Predict / Compounds / SCHEMBL1480002

SCHEMBL1480002

SCHEMBL1480002

Cc1cnc(F)c(C(=O)O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAPRT Q6XQN6 1/20 0.46
▸ KDM4E B2RXH2 4/20 0.44
▸ ASPH Q12797 1/20 0.44
▸ KDM8 Q8N371 1/20 0.44
▸ GABRP O00591 1/20 0.43
▸ GABRD O14764 1/20 0.43
▸ GABRA1 P14867 1/20 0.43
▸ GABRB1 P18505 1/20 0.43
▸ GABRG2 P18507 1/20 0.43
▸ GABRB3 P28472 1/20 0.43
▸ GABRA5 P31644 1/20 0.43
▸ GABRA3 P34903 1/20 0.43
▸ GABRA2 P47869 1/20 0.43
▸ GABRB2 P47870 1/20 0.43
▸ GABRA4 P48169 1/20 0.43
▸ GABRE P78334 1/20 0.43
▸ GABRA6 Q16445 1/20 0.43
▸ GABRG1 Q8N1C3 1/20 0.43
▸ GABRG3 Q99928 1/20 0.43
▸ GABRQ Q9UN88 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL612856 0.79 KDM4E (0.48) KDM4EASPHKDM8GABRPGABRD
SCHEMBL1759837 0.79 NAPRT (0.48) NAPRTKDM4EASPHKDM8GABRP
SCHEMBL31026542 0.78 NAPRT (0.47) NAPRTKDM4EASPHKDM8GABRP
SCHEMBL30968742 0.78 GABRP (0.44) KDM4EASPHKDM8GABRPGABRD
SCHEMBL9508567 0.78 KDM4E (0.47) KDM4EASPHKDM8GABRPGABRD
SCHEMBL1819716 0.78 GABRP (0.44) KDM4EASPHKDM8GABRPGABRD
SCHEMBL5045651 0.78 CSNK2A1 (0.48) KDM4EASPHKDM8GABRPGABRD
SCHEMBL27863346 0.77 GABRP (0.41) NAPRTKDM4EASPHKDM8GABRP
SCHEMBL1516793 0.76 NAPRT (0.46) NAPRTKDM4EASPHKDM8GABRP
SCHEMBL10911361 0.76 SORT1 (0.43) KDM4EASPHKDM8GABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11091501-B2 Heterocyclic compounds as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2021-08-17 — — US disclosed
US-10851115-B2 Heterocyclic compounds as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-12-01 — — US disclosed
US-20190002478-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-01-03 — — US disclosed
US-20190002479-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-01-03 — — US disclosed
WO-2019006291-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2019-01-03 — — WO disclosed
WO-2019006295-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2019-01-03 — — WO disclosed
CN-104812755-B It is used as the pyrazolo pyridine derivatives of TTX S blocking agents 拉夸里亚创药株式会社 2017-08-08 — — CN disclosed
CN-104364235-B Amide derivatives as TTX-S blockers 拉夸里亚创药株式会社 2017-07-04 — — CN disclosed
CN-104812755-A Pyrazolopyridine derivatives as TTX-S blockers RAQUALIA PHARMA INC 2015-07-29 — — CN disclosed
CN-104364235-A Amide derivatives as TTX-S blockers RAQUALIA PHARMA INC 2015-02-18 — — CN disclosed
US-8188071-B2 Amino substituted pyridines as potent kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-29 — — US disclosed
US-8188071-B2 Amino substituted pyridines as potent kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-29 — — US disclosed
US-20110077237-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-31 — — US disclosed
CN-101663276-A 2-aminopyridine derivatives useful as kinase inhibitors VERTEX PHARMA 2010-03-03 — — CN disclosed
EP-2121613-A2 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS Vertex Pharmaceuticals, Inc. (US) 2009-11-25 — — EP disclosed
US-20090124602-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2009-05-14 — — US disclosed
US-20090124602-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2009-05-14 — — US disclosed
US-20090124602-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2009-05-14 — — US disclosed
WO-2008094992-A2 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-08-07 — — WO disclosed
WO-2008094992-A2 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-08-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190002478-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS SIRT1, FURIN, SIRT5 NAPRT 78/4885KDM4E 1342/4885ASPH 820/4885
US-20090124602-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 NAPRT 1808/4885KDM4E 990/4885ASPH 3346/4885
US-11091501-B2 Heterocyclic compounds as RSV inhibitors SIRT1, FURIN, SIRT5 NAPRT 78/4885KDM4E 1342/4885ASPH 820/4885
US-20190002479-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS SIRT1, FURIN, SIRT5 NAPRT 78/4885KDM4E 1342/4885ASPH 820/4885
US-10851115-B2 Heterocyclic compounds as RSV inhibitors SIRT1, FURIN, SIRT5 NAPRT 78/4885KDM4E 1342/4885ASPH 820/4885
US-20110077237-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 NAPRT 1808/4885KDM4E 990/4885ASPH 3346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.